Beta
Back to ISRG.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-chart

ISRG EPS

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for ISRG's EPS in Q1'26 stands at 2.31 USD, reflecting a modest quarter-over-quarter increase from 2.23 USD in Q4'25 and marking the highest value in the observed period. This uptick underscores continued profitability growth, with year-over-year EPS growth at 18.5%. From Q2'23 to Q1'26, ISRG's EPS has exhibited an overall upward trend, rising from 1.2 USD to 2.31 USD, with notable acceleration in the latter half of the period following a dip to 1.18 USD in Q3'23. Year-over-year EPS growth has remained positive throughout, peaking at 85% in Q4'23 before stabilizing around 15-25% in recent quarters, indicating sustained but moderating expansion likely driven by operational efficiencies in the medical device sector. The bar chart visualization highlights consistent quarterly gains, while the overlaid line for YoY growth reveals volatility early on, transitioning to more predictable positive momentum.